Abstract:Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel diseases (IBD), are chronic, relapsing inflammatory disorders of the gastrointestinal (GI) tract. IBD affects over 1 million individuals in the United States and approximately 2.5 million in Europe [1; 2]. Although IBD is a global health concern with the highest prevalence in Western countries, newly industrialized regions in Asia, the Middle East, Africa, and South America have seen a rapid rise in the disease incidence [2]. Despite extensive research, the precise etiology and pathogenesis of IBD remain unclear. However, genome-wide association studies have identified more than 200 IBD-associated susceptibility genes, several of which are involved in mediating host responses to the gut microbiota [3; 4]. This finding has led to increasing interest in the role of the gut microbiota in IBD pathogenesis.The human gut is the home to approximately 100 trillion microorganisms, including bacteria, viruses, fungi, and protozoa, collectively referred to as the gut microbiota. Using culture-independent molecular methods, it is estimated that over 1,000 species of bacteria inhabit the GI tract, and the combined genome of these intestinal microbes contains roughly 100 times more genes than the human genome [5]. More than 99% of intestinal bacteria fall within four major phyla: Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. Of these, the two dominant phyla in healthy adults are Firmicutes and Bacteroidetes [6].The abundance and composition of bacteria vary significantly across different regions of the GI tract. The stomach and upper small intestine host relatively few microbial species, while the number of bacteria increases progressively from the jejunum to the colon [4].Li et al. employed a Mendelian randomization approach to explore the causal relationships between gut microbiota composition and subtypes of CD and UC. The researchers identified specific bacterial taxa, such as Hungatella and Acidaminococcaceae, as protective factors against certain subtypes of IBD, while others like Terrisporobacter and Anaerostipes were associated with increased risk. These findings suggested that dysbiosis may vary between IBD subtypes, with implications for personalized therapeutic interventions targeting specific microbial communities depending on the IBD subtype [3].Expanding on this, Kulecka et al. examined the interaction between gut microbiota and Clostridioides difficile infection (CDI) in patients with IBD and cancer-related diarrhea. The researchers found that IBD and cancer patients both exhibited gut dysbiosis characterized by reduced microbial diversity. CDI further exacerbated this dysbiosis, leading to a significant reduction in beneficial bacteria such as Bacteroides fragilis, while increasing the abundance of pathogenic species like Escherichia coli and Klebsiella pneumoniae. The reduction in short-chain fatty acid (SCFA)-producing bacteria (such as those generating butyrate and propionate) was linked to worsened gut inflammation and disruption of intestinal homeostasis [7].Further exploring systemic connections, Du et al. investigated the concept of lung-gut crosstalk, highlighting the mutual influence between respiratory diseases and IBD. The authors suggested that both lungs and intestines are integral parts of the common mucosal immune system, with immune responses in one organ affecting the other. The review emphasized that gut microbial imbalances could contribute to respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), while respiratory diseases could exacerbate IBD symptoms. The presence of dysbiosis in both conditions suggests potential for shared therapeutic strategies targeting gut microbiota to improve outcomes in both lung and intestinal diseases [8; 9]. In a different vein, Hou et al. focused on the role of the aryl hydrocarbon receptor (AHR) in the context of IBD, with particular attention to how gut microbiota influences AHR activation. The authors discussed how microbial metabolites, such as tryptophan derivatives, can activate AHR, which in turn plays a crucial role in regulating immune responses, inflammation, and maintaining gut barrier integrity. In IBD, a decrease in AHR activity was associated with more severe inflammation and dysbiosis, indicating that therapeutic strategies aimed at enhancing AHR activation could alleviate IBD symptoms. The review also highlighted the potential for non-toxic natural AHR ligands to present as new therapeutic agents.In conclusion, the published studies in this Research Topic highlight the significant importance of gut microbiota in the pathogenesis and management of IBD and irritable bowel syndrome (IBS). Dysbiosis, or the disruption of microbial balance, is a common feature in both IBD and IBS, contributing to inflammation and disease progression [3]. Collectively, these s -Abstract Truncated-

Inflammatory bowel disease as a disorder of an imbalance between pro- and anti-inflammatory molecules and deficiency of resolution bioactive lipids

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Intestinal Inflammation and Regeneration–Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease

Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

Marine Algae and Deriving Biomolecules for the Management of Inflammatory Bowel Diseases: Potential Clinical Therapeutics to Decrease Gut Inflammatory and Oxidative Stress Markers?

Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options

Nutritional Lipids and Mucosal Inflammation

Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside

DAMP-ing IBD: Extinguish the Fire and Prevent Smoldering

Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease

Dissecting Innate and Adaptive Immunity in Inflammatory Bowel Disease: Immune Compartmentalization, Microbiota Crosstalk, and Emerging Therapies

The Microbiome in Inflammatory Bowel Disease

The progression of inorganic nanoparticles and natural products for inflammatory bowel disease

Extraintestinal considerations in inflammatory bowel disease

Editorial: Recent advances in understanding the role and mechanisms of gut microbiota in inflammatory bowel disease and irritable bowel syndrome

Insights and Interventions

Bile acids as inflammatory mediators and modulators of intestinal permeability

Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease